Sharad Chand

Dr. Sharad Chand

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2021 in Clinical Epidemiology and Global Health
Verified
Journal Article
Open access
SCSharad Chand
Sharad Chand
CSC.S. Shastry
C.S. Shastry
SHShivakumar Hiremath
Shivakumar Hiremath
JJJuno J. Joel
Juno J. Joel
CKC.H. Krishnabhat
C.H. Krishnabhat
UMUday Venkat Mateti
Uday Venkat Mateti
Biomedical waste poses various health and environmental hazards. Hence, it should be handled with the utmost care and disposed off safely. Several lacunas exist in the management of biomedical waste in India, and the pandemic posed by the coronavirus has made it even more challenging. The sudden outbreak of the virus led to an exponential rise in the quantity of biomedical waste. Furthermore, the poor infrastructure and lack of human resources have aggravated this situation. To combat this serious problem in a timely manner, the government has formulated various standard operating procedures and has amended the existing rules and guidelines.

5 May 2020 in Journal of Diabetes & Metabolic Disorders
Verified
Journal Article
Closed access
PDF file
MJMerlit James
Merlit James
TVTreesa P. Varghese
Treesa P. Varghese
RSRaghav Sharma
Raghav Sharma
SCSharad Chand
Sharad Chand

1 July 2021 in Clinical Epidemiology and Global Health
Verified
Journal Article
Open access
CCChinju Susan Chacko
Chinju Susan Chacko
SSShravya Lakshmi S
Shravya Lakshmi S
AJAnjali Jayakumar
Anjali Jayakumar
SBSteffy Ligi Binu
Steffy Ligi Binu
RPRamesh Datta Pant
Ramesh Datta Pant
NUNandakumar Up
Nandakumar Up

18 January 2021 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
PKPukar Khanal
Pukar Khanal
RCRupesh V Chikhale
Rupesh V Chikhale
YDYadu Nandan Dey
Yadu Nandan Dey
IPIsmail Pasha
Ismail Pasha
SCSharad Chand
Sharad Chand
Shailendra Shivaji GuravShailendra Shivaji Gurav
Shailendra Shivaji Gurav
Traditionally, Withania somnifera is widely used as an immune booster, anti-viral, and for multiple medicinal purposes. The present study investigated the withanolides as an immune booster and anti-viral agents against the coronavirus-19. Withanolides from Withania somnifera were retrieved from the open-source database, their targets were predicted using DIGEP-Pred, and the protein-protein interaction was evaluated. The drug-likeness score and intestinal absorptivity of each compound were also predicted. The network of compounds, proteins, and modulated pathways was constructed using Cytoscape, and docking was performed using autodock4.0, and selected protein-ligand complexes were subjected to 100 ns Molecular Dynamics simulations. The molecular dynamics trajectories were subjected to free energy calculation by the MM-GBSA method. Withanolide_Q was predicted to modulate the highest number of proteins, showed human intestinal absorption, and was predicted for the highest drug-likeness score. Similarly, combined network interaction identified Withanolide_Q to target the highest number of proteins; RAC1 was majorly targeted, and fluid shear stress and atherosclerosis associated pathway were chiefly regulated. Similarly, Withanolide_D and Withanolide_G were predicted to have a better binding affinity with PLpro, Withanolide_M with 3CLpro, and Withanolide_M with spike protein based on binding energy and number of hydrogen bond interactions. MD studies suggested Withanoside_I with the highest binding free energy (ΔGbind-31.56 kcal/mol) as the most promising inhibitor. Among multiple withanolides from W. somnifera, Withanolide_D, Withanolide_G, Withanolide_M, and Withanolide_Q were predicted as the lead hits based on drug-likeness score, modulated proteins, and docking score to boost the immune system and inhibit the COVID-19 infection, which could primarily act against COVID-19. Communicated by Vsevolod Makeev Graphical Abstract

1 March 2025 in Toxicology Reports
Verified
Journal Article
Open access
VTVatsalya Tiwari
Vatsalya Tiwari
SSShrishti Shandily
Shrishti Shandily
JAJessielina Albert
Jessielina Albert
VMVaibhav Mishra
Vaibhav Mishra
MDManoj Dikkatwar
Manoj Dikkatwar
SCSharad Chand
Sharad Chand
Drug-induced liver injury (DILI) has increasingly become a major concern in Western countries since the late 1960s, with an estimated annual incidence of 13.9-19.1 cases per 100,000 people. DILI is a significant cause of acute liver failure, exhibiting a high mortality rate of 10-50 %. Its etiology includes medications, herbal products, and dietary supplements, exacerbated by pre-existing liver conditions, sonorities, pregnancy, and nutritional deficiencies. It is categorized into intrinsic and idiosyncratic reactions. Intrinsic DILI, dose-dependent and predictable, is primarily caused by substances like paracetamol, which leads to liver toxicity through direct metabolic pathways. In contrast, idiosyncratic DILI is less common, unpredictable, and affects susceptible individuals, with non-steroidal anti-inflammatory drugs, antibiotics, and cardiovascular agents frequently implicated in hospitals. Oxidative stress, mitochondrial dysfunction, bile salt export inhibition, and stress on the endoplasmic reticulum are some DILI-related pathophysiology. Diagnosis relies on biochemical tests, serological markers, radiological investigations, and liver biopsy. Management strategies emphasize the identification and cessation of the offending drugs, supportive care, and specific treatment options targeted to the culprit drugs. Management depends on the severity and nature of the injury.

17 November 2020 in Current Drug Safety
Verified
Journal Article
Closed access
PDF file
SNSunil Nepal
Sunil Nepal
AGAnil Giri
Anil Giri
RBRamesh Bhandari
Ramesh Bhandari
SCSharad Chand
Sharad Chand
SNSudip Nepal
Sudip Nepal
CSChakrakodi Shashidhara Shastry
Chakrakodi Shashidhara Shastry
Pharmaceuticals are beneficial to humankind and emerged as crucial arms to treat/manage multiple disease pathogenesis in the present era. In analogous, these medicines/ medical devices should be used cautiously as they possess a potential threat to induce multiple undesired effects that may be related to human health or the environment. Daunting effects may arise due to the improper disposal of unused/expired medicines. Hence, to minimize such harm, there should be adequate knowledge and practice among the population regarding the safe disposal of unused/expired medicines or related pharmaceutical devices. The lack of approved information regarding safe disposal of such substances may invite serious concerns like environmental pollution, which may induce immediate health hazards to the present population and upcoming future generations. There are numerous ways to dispose of, or manage the unused and expired pharmaceutical substances. Sharing the medicines among siblings, friends, and family members are never free from serious health risks. Storing the unused and expired medicines in the home increases the risk of intentional or accidental ingestion of such substances and may create a health emergency. Disposing medicines like household and municipal waste may lead to environmental pollution and harm to humans and animals. The present review finds the multiple unsafe ways of disposal of unutilized medications/tools. Furthermore, it also summarizes the disposal pattern of unutilized medications among the few developed and undeveloped nations.